Want to Participate in a Clinical Research Trial for Schizophrenia?
Fill out this quick Pre-Screening Questionnaire
- Please complete this form to determine your eligibility for our Schizophrenia studies
Pre-screening questionnaire and your privacy
Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.
Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.
Schizophrenia Clinical Research Studies Available
Schizophrenia Clinical Research Studies
Sponsor:
Neurocrine
Study Name:
Journey Study
Protocol Number:
NBI-98854-ATS3019
Summary: The Journey study is evaluating the safety, efficacy, and tolerability of Valbenazine as Adjunctive or add on treatment in subjects with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment with a previous diagnosis of schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 3-6mg Risperidone equivalent.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 and older
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05110157?term=NBI-98854-ATS3019&draw=2&rank=1
Sponsor Website: https://www.neurocrine.com/
___________________________________________________________________________________________________________________
Sponsor:
Reviva Pharmaceuticals
Study Name:
Recover Study
Protocol Number:
RVP-30-001
Summary: The Recover study is evaluating the safety and efficacy of Brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing exacerbating symptoms of schizophrenia.
- Diagnosis of schizophrenia in in the past 1-20 years.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication and willing to discontinue.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-65
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05184335?term=RVP-30-001&rank=1&tab=table
Sponsor Website: https://revivapharma.com/
___________________________________________________________________________________________________________________
Sponsor:
Click Therapeutics, Inc.
Study Name:
Convoke Study
Protocol Number:
CT-155-R-001
Summary: The Convoke study is evaluating the safety and efficacy of two digital therapeutics as an adjunctive or add on treatment to patients with negative symptoms of schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing exacerbating symptoms of schizophrenia.
- Current diagnosis of schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication.
- Have a device with updated IOS or Android systems and an active email address.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 and older
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05838625?term=CT-155-R001&rank=1&tab=table
Sponsor Website: https://www.clicktherapeutics.com/
___________________________________________________________________________________________________________________
Sponsor:
Recognify Life Sciences
Study Name:
Recognify Study
Protocol Number:
C07-03-02
Summary: The Recognify study is a placebo-controlled study evaluating the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment associated with schizophrenia.
- Diagnosis of schizophrenia for at least 6 months.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for 4 weeks prior to study entry.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- History of taking Clozapine.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-55
Clinicaltrials.gov Link: https://classic.clinicaltrials.gov/ct2/show/record/NCT05686239
Sponsor Website: https://www.recognify.life/
Other clinical research trials available to participants
Clinical research trials and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.
Patients who participate in Excell’s research studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of psychiatric or medical conditions.
We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.
Financial compensation may be available to those who qualify and complete visits for clinical trials at Excell.
Depression Clinical Research Studies
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201
Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 6 weeks prior to entering the study.
- Willing to comply with all study assessments and procedures.
- Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Primary symptoms of post-traumatic stress disorder.
- Clinically significant medical conditions.
- History of substance abuse in the past 3 months.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-70
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website: https://www.altoneuroscience.com/
_____________________________________________________________________________________________
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201 (Decentralized)
Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 6 weeks prior to entering the study.
- Willing to comply with all study assessments and procedures.
- Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Primary symptoms of post-traumatic stress disorder.
- Clinically significant medical conditions.
- History of substance abuse in the past 3 months.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
No
Age:
18-70
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website: https://www.altoneuroscience.com/
______________________________________________________________________________________________
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201 (Decentralized)
Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 6 weeks prior to entering the study.
- Willing to comply with all study assessments and procedures.
- Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Primary symptoms of post-traumatic stress disorder.
- Clinically significant medical conditions.
- History of substance abuse in the past 3 months.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
No
Age:
18-70
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website: https://www.altoneuroscience.com/
____________________________________________________________________________________________
Sponsor:
Janssen Research & Development, LLC
Study Name:
Ventura Study
Protocol Number:
67953964MDD3001
Summary: The Ventura study is a placebo-controlled study evaluating the safety and efficacy of Aticaprant used as adjunctively treatment to an antidepressant. The Ventura study is 13 weeks with 9 study visits in Oceanside, CA.
Eligibility Criteria
Key Inclusion Criteria:
- Current symptoms of depression.
- Currently taking an antidepressant medication for at least 6 weeks.
- Willing to comply with all study assessments and procedures.
- Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- History of noncompliance with current antidepressant therapy.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-74
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1
Sponsor Website: https://www.janssen.com/belgium/rd-janssen
______________________________________________________________________________________________
Sponsor:
Neumora Therapeutics
Protocol Number:
NMRA-335140-301
Summary: The NMRA-335140-301 study is a placebo-controlled study evaluating the safety and efficacy of NMRA-335140 in participants with current depressive symptoms. The study is 16 weeks with 11 scheduled study visits in Oceanside, CA.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression between 4 weeks to 12 months prior to study entry.
- Willing to comply with all study assessments and procedures.
- Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.
Key Exclusion Criteria:
- Diagnosed with post-traumatic stress disorder, bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Unwillingness to discontinue exclusionary psychiatric medications.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-65
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1
Sponsor Website: https://neumoratx.com/
__________________________________________________________________________________________
Sponsor:
Axsome Therapeutics
Protocol Number:
AXS-05-MDD-401
Summary: The AXS-05-MDD-401 study is an active-controlled study of AXS-05 for the prevention of relapse of depressive symptoms. The study is initially 10 weeks with 14 visits in Oceanside, CA with the possibility of a 26-week placebo-controlled extension.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 4 weeks.
- Willing to comply with all study assessments and procedures.
- Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Active post-traumatic stress disorder symptoms in the past 3 years.
- Low or inadequate response to 2 or more antidepressant medications in the current depressive episode.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-65
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT04019704?term=AXS-05&rank=2
Sponsor Website: https://www.axsome.com/
Generalized Anxiety Clinical Research Studies
Sponsor:
Sunovion Pharmaceuticals
Protocol Number:
SEP361-226
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.
Eligibility Criteria:
Key Inclusion Criteria:
- Male or female subject between 18 to 65 years of age.
- Symptoms of Generalized Anxiety Disorder over the past 6 months.
- Primary focus of treatment is Generalized Anxiety Disorder.
Key Exclusion Criteria:
- Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
- Previous inadequate response to more than 3 antidepressant treatments.
- Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table
Sponsor Website:
OCD Clinical Research Studies
Sponsor:
Biohaven Pharmaceuticals
Study Name:
Biohaven Study
Protocol Number:
BHV4157-302
Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.
Eligibility Criteria:
Key Inclusion Criteria:
- Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
- Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
- Willing to stop exclusionary psychiatric medications prior to study entry.
Key Exclusion Criteria:
- Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
- Unwilling to discontinue exclusionary medications or comply with study procedures.
- Any clinically significant unstable medical condition or any clinically significant chronic disease.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1
Sponsor Website:
Adolescent Migraine Clinical Research Studies
Sponsor:
AbbVie
Name:
Periscope Study
Protocol Number:
3110-305-002
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.
Eligibility Criteria
Key Inclusion Criteria:
- History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
- Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.
Key Exclusion Criteria:
- Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
- Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
12-17
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2
_____________________________________________________________________________________________
Sponsor:
AbbVie
Name:
Kaleidoscope Study
Protocol Number:
M21-201
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Atogepant for the preventive treatment of episodic migraine in children and adolescence.
Eligibility Criteria
Key Inclusion Criteria:
- History of 4 to 14 migraine attacks per month with less than 15 headache days 28 days prior to study entry.
- Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.
Key Exclusion Criteria:
- Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
- Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
- History of migraine aura with impairment of level of consciousness, hemiplegic migraine, or retinal migraine.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
12-17
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05711394?term=M21-201&draw=2&rank=1
Resources for Schizophrenia
Schizophrenia
Schizophrenia is a mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.
Schizophrenia involves a range of problems with thinking (cognition), behavior and emotions. Signs and symptoms may vary, but usually involve delusions, hallucinations or disorganized speech, and reflect an impaired ability to function. Symptoms may include:
- Delusions. These are false beliefs that are not based in reality.
- Hallucinations. These usually involve seeing or hearing things that don’t exist.
- Disorganized thinking (speech). Disorganized thinking is inferred from disorganized speech.
- Extremely disorganized or abnormal motor behavior. This may show in a number of ways, from childlike silliness to unpredictable agitation. Behavior isn’t focused on a goal, so it’s hard to do tasks. Behavior can include resistance to instructions, inappropriate or bizarre posture, a complete lack of response, or useless and excessive movement.
- Negative symptoms. This refers to reduced or lack of ability to function normally.
